Mevrin

Quick links to important sections

Mevrin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mevrin

What is Mevrin?

Mevrin is a medication that belongs to a class of drugs known as antispasmodics. It is specifically designed to act on the smooth muscles of the gastrointestinal tract to help manage symptoms associated with functional bowel disorders.

Composition and Mechanism

The active ingredient in Mevrin works by relaxing the muscles in the gut wall. Unlike some other medications that affect the nervous system more broadly, Mevrin is known for its selective action on the digestive system. By reducing muscle spasms and irregular contractions, it helps to normalize the movement of the intestines without significantly impacting normal bowel motility.

Primary Uses

Mevrin is primarily utilized to provide relief from the discomfort and pain associated with various gastrointestinal conditions. It is commonly associated with the management of:

  • Irritable Bowel Syndrome (IBS): Helping to alleviate symptoms such as abdominal pain, cramping, and persistent diarrhea or constipation.
  • Chronic Irritable Colon: Managing long-term sensitivity and discomfort in the lower digestive tract.
  • Spastic Constipation: Addressing localized muscle spasms that can interfere with regular bowel movements.
  • Mucous Colitis: Reducing inflammation-related spasms in the lining of the colon.

Clinical Role

As a therapeutic option, Mevrin is intended to address the underlying muscle hyperactivity that characterizes many functional digestive issues. It is often used as part of a broader approach to digestive health, focusing on the stabilization of the intestinal environment and the reduction of localized physical distress.

What side effects are possible with Mevrin?

Possible Side Effects and Safety Information

Adverse reactions associated with Mevrin (Mebeverine Hydrochloride) are primarily identified through spontaneous reporting during post-marketing use and are often classified as having an unknown frequency in official prescribing documents. These documented effects chiefly involve the immune system and the skin, which reflect the medicine's overall safety profile.


Documented Adverse Reactions

The most significant safety events documented in regulatory sources fall under the categories of Immune System Disorders and Skin and Subcutaneous Tissue Disorders. These typically manifest as allergic reactions, including:

  • Hypersensitivity: Documented instances include urticaria (hives), widespread exanthema (rash), and swelling such as angioedema or face oedema. These reactions are generally classified as Very Rare in regulatory documentation.
  • Serious Adverse Reactions: Within the domain of hypersensitivity, the most serious documented event is anaphylaxis (a severe allergic reaction).

Safety Constraints for Specific Populations

Official regulatory documents define specific high-level constraints for Mebeverine Hydrochloride:

  • Paediatric Use: Use in children and adolescents under 18 years of age is generally not recommended due to insufficient data regarding safety and efficacy in this population.
  • Pregnancy and Lactation: The medicine is not recommended during pregnancy or breastfeeding, as sufficient human data on its effect on the fetus or its presence in breast milk are lacking.
  • Renal/Hepatic Impairment: No specific risk has been identified for individuals with mild to moderate renal or hepatic impairment, and no dosage adjustment is typically considered necessary for these groups.
  • Formulation-Related Contraindications: Certain tablet formulations contain lactose, which mandates a contraindication for individuals with hereditary disorders such as galactose intolerance or Lapp lactase deficiency.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Mevrin

This section summarizes the official descriptions of Mebeverine Hydrochloride overdose as documented in regulatory sources such as the Summary of Product Characteristics (SmPC).


Manifestation and Management Official Regulatory Statement
Documented Clinical Presentation Overdose symptoms are typically reported as absent or mild and are usually rapidly reversible. Observed effects have been documented as being of a neurological and cardiovascular nature.
Theoretical Outcome In cases of very high overdose, the regulatory documents note that CNS excitability may theoretically occur.
Antidote Information No specific antidote is known for Mebeverine Hydrochloride.
Mandated Management Management is defined as symptomatic and supportive treatment. Gastric lavage should only be considered for cases of multiple intoxication or if detected within approximately one hour.

When to Seek Urgent Help

Official guidance mandates that patients should talk to a doctor or go to a hospital straight away if an overdose is suspected or the patient feels unwell. This instruction reinforces the necessity of clinical assessment and professional monitoring of vital functions, even though documented symptoms are often mild. No specific increased risk for elderly or renally/hepatically impaired patients has been identified from post-marketing data regarding overdose severity.

Therapeutic Uses of Mevrin

Main Uses of Mevrin

Mevrin is primarily prescribed for the symptomatic treatment of gastrointestinal conditions characterized by spasms and functional disturbances. The active ingredient, mebeverine, is an antispasmodic that acts directly on the smooth muscle of the digestive tract to alleviate discomfort without affecting normal gut motility.

Irritable Bowel Syndrome (IBS)

The most common application for Mevrin is in the management of Irritable Bowel Syndrome. It is used to address the chronic abdominal pain and bowel irregularities associated with this condition. Specifically, it helps manage:

  • Abdominal pain and cramps: By relaxing the intestinal muscles, it reduces the intensity and frequency of painful spasms.
  • Persistent diarrhea: It helps stabilize bowel movements when they are overactive.
  • Flatulence and bloating: By easing the tension in the gut wall, it can help relieve the feeling of distension.

Other Functional Gastrointestinal Disorders

Beyond IBS, Mevrin is used to treat other functional disorders of the digestive system that involve muscle spasms, including:

  • Chronic irritable colon: Managing long-term sensitivity and discomfort in the large intestine.
  • Spastic constipation: Helping to regulate bowel movements when constipation is caused by muscle spasms rather than a lack of fiber or hydration.
  • Mucous colitis: Addressing inflammation and spasm that lead to the production of excess mucus in the stool.

Primary Benefits

Targeted Action

Mevrin is classified as a musculotropic antispasmodic. This means it works directly on the muscle fibers of the gut. Unlike some other treatments, it does not act through the autonomic nervous system, which significantly reduces the likelihood of systemic side effects like dry mouth or blurred vision.

Preservation of Normal Motility

A key benefit of this medication is its ability to relieve spasms without completely stopping the natural movement (peristalsis) of the intestines. This allows the digestive tract to continue functioning normally while the painful cramps are suppressed.

Symptom Relief and Quality of Life

By addressing the physical symptoms of cramping and bloating, Mevrin aims to reduce the daily physical distress associated with chronic gastrointestinal conditions. This symptomatic relief is intended to help individuals maintain their regular daily activities with less interference from digestive discomfort.

Regulatory References

  1. New Zealand Medicines and Medical Devices Safety Authority

Eligibility and Restrictions for Use

The eligibility for Mevrin (Mebeverine Hydrochloride) is governed strictly by the official population constraints defined in governmental regulatory documents.

Contraindicated Populations

  • Hypersensitivity: Individuals with documented allergy to Mebeverine Hydrochloride or any excipient in the formulation are contraindicated.
  • Excipient Intolerance: The medicine must not be used by patients with rare hereditary problems, such as Galactose Intolerance, Lactase Deficiency, or Glucose-Galactose Malabsorption, due to excipient content.

Age and Reproductive Eligibility Status

Population Regulatory Status
Children/Adolescents (<18 yrs) Not Recommended (Insufficient data on safety/efficacy).
Adults (Including Elderly) Approved for use (Established population).
Pregnancy Not Recommended (Limited human data).
Lactation (Breastfeeding) Should Not Be Used (Unknown excretion in human milk).

Condition-Specific Eligibility

Official labeling for patients with Renal Impairment or Hepatic Impairment states that No Dosage Adjustment is Deemed Necessary, defining these populations as eligible for standard use. These regulatory statements establish the clear boundaries for who is officially permitted, restricted, or prohibited from using the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the interaction profile of Mevrin (Mebeverine), detailing information derived exclusively from official regulatory labeling and government health authority documents.


Documented Interaction Profile

The official interaction profile for Mevrin is characterized by a general absence of known formal drug-drug interactions.

Regulatory authorities report that no formal interaction studies regarding the co-administration of Mevrin with other medicines have been performed. Consequently, regulatory documents do not list specific restrictions or dose adjustments required due to pharmacokinetic (e.g., CYP enzyme-mediated) or pharmacodynamic interactions with other prescription or over-the-counter medications.


Specific Substance Interaction Context

Substance/Class Official Regulatory Statement
Other Medicines No interactions with other medicines are known.
Alcohol Patients can consume alcohol while taking Mevrin, as formal studies have demonstrated the absence of any interaction between mebeverine and ethanol.
Food & Supplements No specific interactions with food, herbal products, or dietary supplements are formally documented in the regulatory labeling.

Interaction Constraints

No formal requirements for timing separation (dosing hours apart) or population-specific interaction adjustments (e.g., for patients with renal or hepatic impairment) are stated in the official interaction documentation.

Mechanism of Action

Mevrin (mebeverine) exerts its primary action by targeting the smooth muscle cells within the gastrointestinal tract, demonstrating a high degree of selective accumulation in this tissue. The agent functions as a spasmolytic primarily through the modulation of ion channel activity. Mechanistically, Mevrin acts as an inhibitor of voltage-dependent calcium channels, specifically reducing the transmembrane influx of calcium ions (Ca^2+) into the smooth muscle cell cytoplasm. The decrease in intracellular Ca^2+ concentration attenuates the calcium-calmodulin-myosin light chain kinase cascade, resulting in a reduction of the actin-myosin cross-bridge cycling necessary for muscular contraction. A secondary mechanism involves the potential modulation of sodium channels and a local anesthetic-like effect on the gut musculature, further diminishing membrane excitability. The downstream cascade results in the relaxation of intestinal smooth muscle, which modulates the systemic physiological consequence of hypermotility.

Dosage and Administration Information

How Mevrin is Used: Official Administration Guidelines

Mebeverine Hydrochloride (Mevrin) is used according to specific instructions to ensure the correct drug exposure and timing in relation to food intake.

Administration Scope

Feature Official Administration Instructions
Route of Administration The only approved route for Mevrin is oral use.
Official Dosage Forms Available as 135 mg Film-coated Tablets and 200 mg Modified-release Capsules.
Dosing Schedule (Adults) 135 mg Tablets: One tablet three times a day (total 405 mg daily). 200 mg MR Capsules: One capsule twice a day (total 400 mg daily).
Timing in Relation to Meals The medication should be taken preferably 20 minutes before meals.
Missed-Dose Rules If a dose is missed, it must be skipped, and the patient should take the next dose at the usual time; a double dose must not be taken to compensate.
Special Procedural Conditions The tablets or capsules must be swallowed whole with an adequate amount of water and must not be chewed to maintain the intended release profile.

Population-Specific Use

No dosage adjustment is deemed necessary for older adults (the elderly) or for individuals with known renal or hepatic impairment. Conversely, the 135 mg tablets and 200 mg modified-release capsules are not recommended for use in children and adolescents under 18 years of age due to insufficient supporting data. The overall duration of use is not typically limited for the management of symptoms, and a dose reduction may be considered after several weeks once a satisfactory effect has been achieved.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mevrin

Evidence for use in Irritable Bowel Syndrome (IBS) and Functional Bowel Disorders

Research for Mevrin was studied for conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome and other functional bowel disorders. The evidence base includes Randomized Controlled Trials (RCTs) that research examined by assigning people to Mevrin or a comparison substance or treatment. Subsequent systematic reviews have been applied in studies examining patient-reported experiences to synthesize the overall research.

These studies were used in research exploring how symptoms change over time, primarily monitoring patient-reported outcomes describing perceived discomfort. Researchers examined outcomes related to physical discomfort, specifically measuring the frequency and intensity of abdominal pain and cramping, as well as bloating. Findings from these controlled trials show patterns related to the measures collected during the study period. Mevrin was also evaluated in settings to understand how measured outcomes compared to both an inactive substance (placebo) and other available antispasmodic agents.

Limitations of the Research and Remaining Gaps

Controlled research for Mevrin, particularly the rigorous RCTs, was observed in studies over relatively short-term periods, often lasting between two and six weeks. Data on long-term effects are not fully established by the same level of rigorous controlled research. While some observational data exist for longer periods, the evidence quality varies across studies when compared to RCTs.

Evidence quality varies across studies, particularly among older research, which sometimes suffered from modest sample sizes or varying definitions of a successful outcome. This methodological variation contributes to statistical heterogeneity found in pooled analyses. Furthermore, while the evidence base includes patients with different IBS subtypes, certainty remains low for some subgroup findings due to limited statistical power.

Frequently Asked Questions (FAQ)

Common questions about Mevrin (FAQ)


Q: How long does it usually take for Mevrin to start working?

Official product information suggests that Mevrin (mebeverine) typically begins to show effects after approximately one hour following administration. The medication works directly on the smooth muscle in the gastrointestinal tract.

Q: What is the longest someone typically stays on Mevrin?

According to official regulatory documents, the overall duration of use for Mevrin is not typically limited for the management of symptoms. The medication is not explicitly defined as a short-term treatment in regulatory documents.

Q: Are there generic versions of Mevrin available?

Mevrin is a recognized brand name for the active ingredient mebeverine hydrochloride. The active ingredient is available under several different brand and generic names from various manufacturers.

Q: Can Mevrin cause changes in mood or sleep patterns?

While the primary side effects often involve allergic reactions, official product information has noted nervous system disorders in some reports. These have included effects such as dizziness, headache, and insomnia (difficulty sleeping).

Q: Is it okay to drive while taking Mevrin?

Regulatory documents state that mebeverine has no or negligible influence on the ability to drive or use machinery. However, if you experience side effects like dizziness, you should discuss with a healthcare professional before driving or operating machinery.

Q: Does Mevrin interact with caffeine?

Official interaction studies regarding the co-administration of Mevrin with substances like caffeine have not been formally documented in the regulatory labeling. The product has a general absence of known formal drug-drug interactions.

Q: Can women who are planning pregnancy take Mevrin?

Mevrin is not recommended for use during pregnancy because there is limited human data available on its effects. Regulatory documents recommend consulting a healthcare professional when planning pregnancy.

Q: Are the side effects of Mevrin permanent?

Reported symptoms following an accidental overdose were described as usually rapidly reversible or mild in regulatory documents. Generally, side effects are expected to resolve upon discontinuation of the medicine.

Q: Does Mevrin show up on standard drug tests?

Some official regulatory documentation has stated that mebeverine does not produce false positive reactions in standard diagnostic urine tests.

Q: Are there any foods that can reduce the effectiveness of Mevrin?

No specific interactions with food, herbal products, or dietary supplements are formally documented in the official regulatory labeling. This indicates the medicine is not known to be affected by specific foods.

Q: What is the typical time frame for the maximum effect of Mevrin?

Pharmacokinetic data indicate that the main active metabolite of Mevrin reaches its maximum concentration in the body at approximately 3 hours after taking the modified-release capsule formulation. This time frame relates to the concentration of the drug in the system.

Q: Are there any rare but serious side effects associated with Mevrin?

Yes, although all side effects are generally uncommon, the most serious documented rare adverse reaction related to hypersensitivity is a severe allergic reaction known as anaphylaxis.

Q: Are there special considerations for taking Mevrin in warmer climates?

Official storage instructions require Mevrin to be kept in a dry place at a temperature not above 30°C and protected from light. Consulting the storage guidelines is important, particularly in warmer climates.

Q: Is it normal to feel tired when first starting Mevrin?

Tiredness is not specifically listed as a common side effect. However, known adverse reactions reported in official documents can include central nervous system effects such as dizziness and headache.

Q: Does Mevrin affect fertility in men or women?

Official product information states that there are no clinical data on the effects of mebeverine on human male or female fertility. However, animal studies conducted with the substance did not indicate harmful effects on fertility.

Q: Does Mevrin interact with hormonal contraceptives?

No formal interaction studies regarding the co-administration of Mevrin with other medicines, including hormonal contraceptives, have been performed or documented in the regulatory labeling.

Q: Are there any dietary restrictions when taking Mevrin?

According to official regulatory documents, there are no specific dietary restrictions or formally documented interactions with food, herbal products, or supplements associated with Mevrin.

Q: What are the most commonly reported side effects of Mevrin?

The most significant documented adverse reactions chiefly involve the immune system and skin. These have included urticaria (hives), a widespread rash (exanthema), and swelling such as angioedema or face oedema.

Q: Does Mevrin cause weight gain or loss?

Official regulatory documents focusing on adverse reactions typically list immune and skin disorders. There is no mention of weight gain or weight loss in the documented safety profile from regulatory sources.

Q: What kind of interactions should I look out for if I take Mevrin?

Official regulatory labeling is characterized by a general absence of known formal drug-drug interactions. While no specific restrictions are listed, patients are advised to review all medications, including over-the-counter products, with a healthcare professional.

Q: What does the research say about the long-term effects of Mevrin?

Controlled research for Mevrin, such as rigorous Randomized Controlled Trials (RCTs), was generally conducted over relatively short-term periods. Consequently, the data on long-term effects are not fully established by the same level of controlled research.

Q: What are the signs of an allergic reaction to Mevrin?

Signs of a documented allergic reaction (hypersensitivity) may include skin issues like hives (urticaria), a widespread rash, or swelling such as angioedema. A severe allergic reaction known as anaphylaxis is also documented.

Q: What are the common reasons people stop taking Mevrin?

Based on research observations, common reasons for stopping similar medications often relate to a lack of sufficient efficacy (the medicine not helping symptoms) or the occurrence of side effects. Researchers monitor patient outcomes regarding discomfort, suggesting these are the primary factors in continuation.

Q: Does Mevrin affect blood pressure or heart rate?

The main documented adverse reactions of Mevrin are focused on immune and skin disorders. Systemic effects such as changes in blood pressure or heart rate are not mentioned in the regulatory documents detailing the known adverse reaction profile.

How should Mevrin be stored and disposed of?

Storage and Disposal Requirements

Mevrin (Mebeverine Hydrochloride) must be stored under specific environmental conditions to maintain stability, as required by official regulatory labeling.

Requirement Category Official Instructions
Temperature & Protection Store in a dry place at a temperature not above 30°C and protected from light.
Container & Stability Keep the medicine in the original container and do not use it after the expiry date (EXP).
Child Safety Keep this medicine out of the sight and reach of children.
Disposal Do not throw away unused or expired product via wastewater or household waste. Consult a pharmacist for proper disposal methods.

These rules ensure the product's quality remains consistent until the end of its labeled shelf-life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mevrin found in:

A-Z Index: